Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

gren

Showing results (311-320 of 322) with videos related to

Pageof 33
Sort By:
Journal of Medicinal Chemistry|October 10, 2008
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseasesClark A Sehon, Gren Z Wang, Andrew Q Viet, et al.
Bioorganic & Medicinal Chemistry Letters|November 4, 2011
CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole bloodGren Z Wang, Pamela A Haile, Tom Daniel, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
The Journal of Organic Chemistry|July 9, 2016
Effect of Buffer Conditions and Organic Cosolvents on the Rate of Strain-Promoted Azide-Alkyne CycloadditionDerek L Davis, Erin K Price, Sabrina O Aderibigbe, et al.
Journal of Medicinal Chemistry|January 5, 2007
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitorsKrista B Goodman, Haifeng Cui, Sarah E Dowdell, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profilesJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory DiseasesPamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
ACS Medicinal Chemistry Letters|October 23, 2018
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Intensive Care Medicine Experimental|September 15, 2019
Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate modelGuillaume Poliquin, Duane Funk, Shane Jones, et al.
Pageof 33

Showing results (311-320 of 322) with videos related to

Sort By:
Pageof 33
Journal of Medicinal Chemistry|October 10, 2008
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseasesClark A Sehon, Gren Z Wang, Andrew Q Viet, et al.
Bioorganic & Medicinal Chemistry Letters|November 4, 2011
CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole bloodGren Z Wang, Pamela A Haile, Tom Daniel, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
The Journal of Organic Chemistry|July 9, 2016
Effect of Buffer Conditions and Organic Cosolvents on the Rate of Strain-Promoted Azide-Alkyne CycloadditionDerek L Davis, Erin K Price, Sabrina O Aderibigbe, et al.
Journal of Medicinal Chemistry|January 5, 2007
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitorsKrista B Goodman, Haifeng Cui, Sarah E Dowdell, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profilesJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory DiseasesPamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
ACS Medicinal Chemistry Letters|October 23, 2018
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Intensive Care Medicine Experimental|September 15, 2019
Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate modelGuillaume Poliquin, Duane Funk, Shane Jones, et al.
Pageof 33